ClinicalTrials.gg
Active, not recruitingNCT05468489Updated Nov 12, 2026

To Evaluate Efficacy and Safety of Serplulimab + Chemotherapy (Carboplatin- Etoposide) in US Patients With ES-SCLC

A Phase 2 interventional study of Serplulimab + chemotherapy (carboplatin-etoposide) and Atezolizumab + chemotherapy (carboplatin-etoposide) in Extensive Stage Small Cell Lung Cancer, sponsored by Shanghai Henlius Biotech. Active, not recruiting at 65 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Shanghai Henlius Biotech (part of Fosun Pharma) · Phase 2, Interventional, and Treatment

Updated Nov 12, 2026Eligibility revisedDesign changed+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 629 studies in Small Cell Lung Carcinoma with a site in United States — 111 open to participants now, 182 under way, 26 of them phase 3. Small Cell Lung Carcinoma · United States.

Planned enrollment
105th of 550
200 · median 55
Started
2022
with 25 others
Phase 2
186 of 629
24 open now
Primary completion
2026-02
later than 31 of 181 live
Registered
503rd of 629
by date

Among the 629 studies in Small Cell Lung Carcinoma with a site in United States, this one is the 105th largest by planned enrollment of the 550 interventional ones that give a count, is one of 26 that started in 2022, is one of 186 in phase 2, reaches primary completion later than 31 of the 181 other live ones, and was the 503rd registered.

Small Cell Lung Carcinoma

1,301 studies on the registry are indexed under Small Cell Lung Carcinoma; 365 are open to participants now.

Browse Small Cell Lung Carcinoma studies →

Open to participants now

111 of the 629 studies in Small Cell Lung Carcinoma with a site in United States are open now. Recruiting first, the newest first:

106 more — sign in →

All 111 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 265 Small Cell Lung Carcinoma studies recruiting now, 175 (66%) set no upper age limit and 66 (25%) stop at 75 or younger; 3 take children under 18; 8 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 629 studies in Small Cell Lung Carcinoma with a site in United States, or all of them as a file.
02

Study summary

This is a randomized, open-label study of Serplulimab plus chemotherapy (Carboplatin-Etoposide) in comparison with Atezolizumab plus chemotherapy in previously untreated US patients with ES-SCLC.

Subjects in this study will be randomized to arm A or B at 1:1 ratio as follows:

  • Arm A (Serplulimab): Serplulimab + chemotherapy (carboplatin-etoposide)
  • Arm B (control): Atezolizumab + chemotherapy (carboplatin-etoposide)
03

Conditions studied

  • Extensive Stage Small Cell Lung Cancer

Keywords

  • Extensive Stage Small Cell Lung Cancer
  • Anti-PD-1 Monoclonal Antibody
04

Who can participate

The criteria were revised on the registry on Nov 12, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Voluntary participation in clinical studies.

Male or female aged ≥ 18 years at the time of signing the ICF.

or cytologically diagnosed with ES-SCLC (according to the Veterans Administration Lung Study Group staging system).

No prior systemic therapy for ES-SCLC.

Patients who have received chemoradiotherapy for previous limited stage SCLC must be treated with curative intent and have a treatment-free interval of at least 6 months from the last course of chemotherapy, radiotherapy, or chemoradiotherapy to the diagnosis of extensive stage SCLC.

At least one as assessed according to 1.1 within 4 weeks prior to randomization.

Every effort should be made to provide tumor tissues for the determination of expression.

Prior antineoplastic therapy including Chinese medicine therapy, which has been approved as antineoplastic therapy by NMPA or its instruction has antineoplastic therapy effect, must have been ≥ 2 weeks from the first dose in this study with treatment-related AEs resolved to Grade ≤ 1 (except for Grade 2 alopecia).

An PS score of 0 or 1.

An expected survival ≥ 12 weeks.

Subjects with prior denosumab use that can and agree to switch to bisphosphonate therapy for bone starting prior to randomization and throughout treatment.

Normal major organ functions.

Female patients must meet one of the following conditions: Menopause, Surgically sterilized or of , must meet the following: negative serum pregnancy test within 7 days prior to randomization and agree to use methods with an annual failure rate \<1% or maintain abstinence. Must not be breast-feeding.

Male patients must: agree to abstinence or take contraception measures as follows: male patients with a pregnant partner or a partner of childbearing potential must remain abstinent or use a condom or had vasectomy to prevent embryonic exposure during study treatment and for at least 6 months after the last dose of study drug. Periodic abstinence and external ejaculation are ineligible methods of contraception.

Exclusion criteria

Exclusion Criteria:

or cytologically confirmed mixed SCLC.

Other active within 5 years or at the same time. Localized tumors that have been cured, such as basal cell carcinoma, squamous-cell skin cancer, superficial bladder cancer, prostate carcinoma in situ, cervical cancer in situ and breast cancer in situ are acceptable.

Patients who are preparing for or have received an organ or bone marrow transplant.

Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures (once monthly or more frequently). Patients with indwelling catheters are allowed regardless of drainage frequency.

Patients with known or documented active and/or carcinomatous meningitis at screening. However, the following subjects are allowed to be enrolled: 1) Subjects with asymptomatic brain metastases may be included but are required to receive regular brain imaging as a site of lesion. 2) Subjects with treated brain metastases which have been stable for at least 2 weeks, with no evidence of new or enlarging brain metastases, and with discontinued 3 days prior to study drug administration.

Subjects with spinal cord compression that has not been treated with surgery and/or radiotherapy.

Patients with myocardial infarction within half a year before the first dose of the study drug, poorly controlled arrhythmia.

Class III to IV cardiac insufficiency according to classification.

Subject has uncontrolled or symptomatic hypercalcemia.

Subject with peripheral neuropathy ≥ Grade 2 by .

(HIV) infection, positive test for HIV antibody.

Active or latent pulmonary tuberculosis.

Subjects with previous and concurrent interstitial pneumonia, pneumoconiosis, radiation pneumonitis, drug-related pneumonitis and severe impaired pulmonary function that may interfere with the detection and management of suspected drug-related pulmonary toxicity, as judged by the investigator.

or or Hepatitis B and C co-infection.

Known active or suspected diseases. Subjects in a stable state with no need for systemic therapy are allowed to enroll.

Have received treatment with within 28 days prior to the first administration. Subjects may receive inactivated viral vaccines for seasonal influenza but may not receive live attenuated influenza vaccines via intranasal route.

Subjects requiring treatment with systemic corticosteroids or other immunosuppressive drugs within 14 days prior to the first dose or during the study. However, in the absence of active autoimmune disease, subjects are allowed to use topical or inhaled steroids and adrenal hormone replacement therapy at doses equivalent to ≤ 10 mg/day of prednisone efficacy.

With any active infection requiring systemic anti-infective treatment at the time of first dose of study treatment.

Major surgery within 28 days prior to the first dose of the study drug, defined as: surgeries requiring at least 3 weeks of recovery to be able to receive treatment in this study.

Radical radiation therapy within 3 months prior to study medications. Note: Palliative radiotherapy to bone or palliative radiotherapy to superficial lesions is allowed according to local standards 14 days prior to the first dose. Radiotherapy covering more than 30% of the bone marrow area within 28 days prior to the first dose is not allowed.

The subject has previously received other antibodies/drugs against immune checkpoints, such as , PD-L1, CTLA4, etc.

Participation in any other ongoing clinical studies, or less than 14 days from the end of the previous clinical study treatment to the start of this trial.

Known history of severe allergy to any monoclonal antibody.

Known to carboplatin or etoposide.

Pregnant or lactating females.

Active use of psychotropics abuse or drug abuse.

In the judgment of the investigator, the subject has any other factors that may lead to a premature discontinuation.

Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
200 participants (estimated)

Study arms

  • Experimental
    Serplulimab + chemotherapy

    Serplulimab + chemotherapy (carboplatin-etoposide)

    Drug: Serplulimab + chemotherapy (carboplatin-etoposide)

  • Active comparator
    Atezolizumab + chemotherapy

    Atezolizumab + chemotherapy (carboplatin-etoposide)

    Drug: Atezolizumab + chemotherapy (carboplatin-etoposide)

Interventions

  • DrugSerplulimab + chemotherapy (carboplatin-etoposide)

    Drug: Serplulimab is an innovative monoclonal antibody targeting PD-1,developed by Shanghai Henlius Biotech, Inc. Drug: carboplatin and etoposide chemotherapeutics

  • DrugAtezolizumab + chemotherapy (carboplatin-etoposide)

    Drug: Atezolizumab is a monoclonal antibody targeting PD-L1,developed by Roche Pharma AG. Drug: carboplatin and etoposide chemotherapeutics

This study also gives Atezolizumab. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. OS

    Overall assessment

    Time frame: A period from randomization through death regardless of causality (approximately up to 24 months).

Secondary outcomes

  1. Objective response rate (ORR)

    Objective response rate (ORR) (assessed by independent radiology review committee \[IRRC\] and the investigator based on Response Evaluation Criteria in Solid Tumors \[RECIST\] 1.1)

    Time frame: approximately up to 14 months

  2. Progression-free survival (PFS)

    Progression-free survival (PFS) (assessed by IRRC and the investigator based on RECIST 1.1)

    Time frame: approximately up to 24 months

  3. PFS2

    PFS2 (assessed by the investigator based on RECIST 1.1)

    Time frame: Approximately up to 24 months

  4. Duration of response (DOR)

    Duration of response (DOR) (assessed by IRRC and the investigator based on RECIST 1.1)

    Time frame: Approximately up to 24 months

  5. Adverse events

    Number of Participants With Abnormal Laboratory Values and/or Adverse Events That Are Related to Treatment.

    Time frame: approximately up to 24 months

  6. Observed concentration of HLX10 in serum

    Observed concentration of HLX10 in serum

    Time frame: Approximately up to 24 months

  7. Estimated PK exposure of HLX10 in serum from population pharmacokinetic analysis, expressed as mg·h/L

    The PK data obtained in this study will be pooled with other data from HLX10 (Serplulimab) clinical trials for further population pharmacokinetic analyses. The differences in PK exposure between American population and the obtained populations (Asian and non-Asian) will be compared through model simulation.

    Time frame: Approximately up to 24 months

  8. HLX10 anti-drug antibody (ADA)

    HLX10 anti-drug antibody (ADA)

    Time frame: Approximately up to 24 months

  9. Neutralizing antibody (NAb)

    Neutralizing antibody (NAb) positive rate

    Time frame: Approximately up to 24 months

  10. Quality of life assessment

    Lung cancer Quality of life assessment

    Time frame: Approximately up to 24 months

Other outcomes

  1. Exploratory Endpoint

    Potential prognostic and predictive biomarkers, including PD-L1 expression in tumor tissue and SCLC-related blood biomarker

    Time frame: Approximately up to 24 months

07

Study locations

65 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2022 to primary completion in Feb 2026, 39 months.

Of 54 industry-sponsored phase 2 interventional studies under Small Cell Lung Carcinoma, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 44. This study's 39 months is above that.

Counting every sponsor, half of 204 studies reached it within 46 months; a quarter within 29 and three quarters within 84.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 11, 2022
First posted
Jul 21, 2022
StartActual
Nov 18, 2022
Primary completionActual
Feb 28, 2026
CompletionEst.
Dec 31, 2027
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
2 sites added, 4 sites removed
Show 2 added (2 United States)
  • Straub Benioff Medical Center · Honolulu, United States
  • Lankenau Medical Center · Wynnewood, United States
Show 4 removed
  • Banner MD Anderson Cancer Center (BMDACC) · Greeley, United States
  • Lahey Hospital & Medical Center · Burlington, United States
  • North Mississippi Medical Center Hematology and Oncology Clinic · Tupelo, United States
  • Monument Health · Rapid City, United States
Nov 12, 2026
Eligibility
Criteria largely rewritten (32 changes)
What changed in the criteria
Inclusion criteria
  • AddedPatients who have received chemoradiotherapy for previous limited stage SCLC must be treated with curative intent and have a treatment-free interval of at least 6 months from the last course of chemotherapy, radiotherapy, or chemoradiotherapy to the diagnosis of extensive stage SCLC.
  • RemovedMajor organs are functioning well.
  • AddedPrior antineoplastic therapy including Chinese medicine therapy, which has been approved as antineoplastic therapy by NMPA or its instruction has antineoplastic therapy effect, must have been ≥ 2 weeks from the first dose in this study with treatment-related AEs resolved to NCI-CTCAE Grade ≤ 1 (except for Grade 2 alopecia).
  • RemovedParticipant must keep contraception.
  • AddedNormal major organ functions.
  • AddedFemale patients must meet one of the following conditions: Menopause, Surgically sterilized or of child-bearing potential, must meet the following: negative serum pregnancy test within 7 days prior to randomization and agree to use birth control methods with an annual failure rate <1% or maintain abstinence. Must not be breast-feeding.
  • AddedMale patients must: agree to abstinence or take contraception measures as follows: male patients with a pregnant partner or a partner of childbearing potential must remain abstinent or use a condom or had vasectomy to prevent embryonic exposure during study treatment and for at least 6 months after the last dose of study drug. Periodic abstinence and external ejaculation are ineligible methods of contraception.
Exclusion criteria
  • AddedOther active malignancies within 5 years or at the same time. Localized tumors that have been cured, such as basal cell carcinoma, squamous-cell skin cancer, superficial bladder cancer, prostate carcinoma in situ, cervical cancer in situ and breast cancer in situ are acceptable.
  • AddedPatients who are preparing for or have received an organ or bone marrow transplant.
  • AddedUncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures (once monthly or more frequently). Patients with indwelling catheters are allowed regardless of drainage frequency.
  • AddedPatients with known or documented active CNS metastases and/or carcinomatous meningitis at screening. However, the following subjects are allowed to be enrolled: 1) Subjects with asymptomatic brain metastases may be included but are required to receive regular brain imaging as a site of lesion. 2) Subjects with treated brain metastases which have been stable for at least 2 weeks, with no evidence of new or enlarging brain metastases, and with discontinued steroids 3 days prior to study drug administration.
  • AddedSubjects with spinal cord compression that has not been treated with surgery and/or radiotherapy.
  • AddedClass III to IV cardiac insufficiency according to NYHA classification.
  • AddedSubject has uncontrolled or symptomatic hypercalcemia.
  • AddedSubject with peripheral neuropathy ≥ Grade 2 by CTCAE.
  • AddedHuman immunodeficiency virus (HIV) infection, positive test for HIV antibody.
  • AddedActive or latent pulmonary tuberculosis.
  • AddedSubjects with previous and concurrent interstitial pneumonia, pneumoconiosis, radiation pneumonitis, drug-related pneumonitis and severe impaired pulmonary function that may interfere with the detection and management of suspected drug-related pulmonary toxicity, as judged by the investigator.
  • AddedHepatitis B or Hepatitis C or Hepatitis B and C co-infection.
  • AddedKnown active or suspected autoimmune diseases. Subjects in a stable state with no need for systemic immunosuppressant therapy are allowed to enroll.
  • AddedHave received treatment with live vaccines within 28 days prior to the first administration. Subjects may receive inactivated viral vaccines for seasonal influenza but may not receive live attenuated influenza vaccines via intranasal route.
  • AddedSubjects requiring treatment with systemic corticosteroids or other immunosuppressive drugs within 14 days prior to the first dose or during the study. However, in the absence of active autoimmune disease, subjects are allowed to use topical or inhaled steroids and adrenal hormone replacement therapy at doses equivalent to ≤ 10 mg/day of prednisone efficacy.
  • AddedWith any active infection requiring systemic anti-infective treatment at the time of first dose of study treatment.
  • AddedMajor surgery within 28 days prior to the first dose of the study drug, defined as: surgeries requiring at least 3 weeks of recovery to be able to receive treatment in this study.
  • AddedRadical radiation therapy within 3 months prior to study medications. Note: Palliative radiotherapy to bone or palliative radiotherapy to superficial lesions is allowed according to local standards 14 days prior to the first dose. Radiotherapy covering more than 30% of the bone marrow area within 28 days prior to the first dose is not allowed.
  • AddedThe subject has previously received other antibodies/drugs against immune checkpoints, such as PD-1, PD-L1, CTLA4, etc.
  • AddedParticipation in any other ongoing clinical studies, or less than 14 days from the end of the previous clinical study treatment to the start of this trial.
  • EditedPregnant or breastfeedinglactating females.
  • RemovedPatients with a known history of psychotropic drug abuse or drug addiction.
  • RemovedPatients who have other factors that could lead to the early termination of this study based on the investigator's judgment.
  • AddedActive use of psychotropics abuse or drug abuse.
  • AddedIn the judgment of the investigator, the subject has any other factors that may lead to a premature discontinuation.
Nov 12, 2026
Secondary outcomes
11 added, 6 removed
What changed in the outcomes
  • AddedObjective response rate (ORR)Time frame: approximately up to 14 months
  • AddedProgression-free survival (PFS)Time frame: approximately up to 24 months
  • AddedPFS2Time frame: Approximately up to 24 months
  • AddedDuration of response (DOR)Time frame: Approximately up to 24 months
  • AddedAdverse eventsTime frame: approximately up to 24 months
  • AddedObserved concentration of HLX10 in serumTime frame: Approximately up to 24 months
  • AddedEstimated PK exposure of HLX10 in serum from population pharmacokinetic analysis, expressed as mg·h/LTime frame: Approximately up to 24 months
  • AddedHLX10 anti-drug antibody (ADA)Time frame: Approximately up to 24 months
  • AddedNeutralizing antibody (NAb)Time frame: Approximately up to 24 months
  • AddedQuality of life assessmentTime frame: Approximately up to 24 months
  • RemovedORRTime frame: approximately up to 14 months
  • RemovedPFSTime frame: approximately up to 24 months
  • RemovedNumber of participants with treatment-related adverse events as assessed by CTCAE v5.0Time frame: approximately up to 24 months
  • RemovedMaximum Plasma Concentration (Cmax)Time frame: approximately up to 24 months
  • RemovedMinimum Plasma Concentration (Cmin)Time frame: approximately up to 24 months
  • RemovedAverage Plasma Concentration (Cavg)Time frame: approximately up to 24 months
  • Addedother outcomeExploratory EndpointTime frame: Approximately up to 24 months
Nov 12, 2026
Design
Phase 3→Phase 2
Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    2 sites added, 4 sites removed
    Show 2 added (2 United States)
    • Straub Benioff Medical Center · Honolulu, United States
    • Lankenau Medical Center · Wynnewood, United States
    Show 4 removed
    • Banner MD Anderson Cancer Center (BMDACC) · Greeley, United States
    • Lahey Hospital & Medical Center · Burlington, United States
    • North Mississippi Medical Center Hematology and Oncology Clinic · Tupelo, United States
    • Monument Health · Rapid City, United States
    Eligibility Criteria largely rewritten (32 changes)
    What changed in the criteria
    Inclusion criteria
    • AddedPatients who have received chemoradiotherapy for previous limited stage SCLC must be treated with curative intent and have a treatment-free interval of at least 6 months from the last course of chemotherapy, radiotherapy, or chemoradiotherapy to the diagnosis of extensive stage SCLC.
    • RemovedMajor organs are functioning well.
    • AddedPrior antineoplastic therapy including Chinese medicine therapy, which has been approved as antineoplastic therapy by NMPA or its instruction has antineoplastic therapy effect, must have been ≥ 2 weeks from the first dose in this study with treatment-related AEs resolved to NCI-CTCAE Grade ≤ 1 (except for Grade 2 alopecia).
    • RemovedParticipant must keep contraception.
    • AddedNormal major organ functions.
    • AddedFemale patients must meet one of the following conditions: Menopause, Surgically sterilized or of child-bearing potential, must meet the following: negative serum pregnancy test within 7 days prior to randomization and agree to use birth control methods with an annual failure rate <1% or maintain abstinence. Must not be breast-feeding.
    • AddedMale patients must: agree to abstinence or take contraception measures as follows: male patients with a pregnant partner or a partner of childbearing potential must remain abstinent or use a condom or had vasectomy to prevent embryonic exposure during study treatment and for at least 6 months after the last dose of study drug. Periodic abstinence and external ejaculation are ineligible methods of contraception.
    Exclusion criteria
    • AddedOther active malignancies within 5 years or at the same time. Localized tumors that have been cured, such as basal cell carcinoma, squamous-cell skin cancer, superficial bladder cancer, prostate carcinoma in situ, cervical cancer in situ and breast cancer in situ are acceptable.
    • AddedPatients who are preparing for or have received an organ or bone marrow transplant.
    • AddedUncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures (once monthly or more frequently). Patients with indwelling catheters are allowed regardless of drainage frequency.
    • AddedPatients with known or documented active CNS metastases and/or carcinomatous meningitis at screening. However, the following subjects are allowed to be enrolled: 1) Subjects with asymptomatic brain metastases may be included but are required to receive regular brain imaging as a site of lesion. 2) Subjects with treated brain metastases which have been stable for at least 2 weeks, with no evidence of new or enlarging brain metastases, and with discontinued steroids 3 days prior to study drug administration.
    • AddedSubjects with spinal cord compression that has not been treated with surgery and/or radiotherapy.
    • AddedClass III to IV cardiac insufficiency according to NYHA classification.
    • AddedSubject has uncontrolled or symptomatic hypercalcemia.
    • AddedSubject with peripheral neuropathy ≥ Grade 2 by CTCAE.
    • AddedHuman immunodeficiency virus (HIV) infection, positive test for HIV antibody.
    • AddedActive or latent pulmonary tuberculosis.
    • AddedSubjects with previous and concurrent interstitial pneumonia, pneumoconiosis, radiation pneumonitis, drug-related pneumonitis and severe impaired pulmonary function that may interfere with the detection and management of suspected drug-related pulmonary toxicity, as judged by the investigator.
    • AddedHepatitis B or Hepatitis C or Hepatitis B and C co-infection.
    • AddedKnown active or suspected autoimmune diseases. Subjects in a stable state with no need for systemic immunosuppressant therapy are allowed to enroll.
    • AddedHave received treatment with live vaccines within 28 days prior to the first administration. Subjects may receive inactivated viral vaccines for seasonal influenza but may not receive live attenuated influenza vaccines via intranasal route.
    • AddedSubjects requiring treatment with systemic corticosteroids or other immunosuppressive drugs within 14 days prior to the first dose or during the study. However, in the absence of active autoimmune disease, subjects are allowed to use topical or inhaled steroids and adrenal hormone replacement therapy at doses equivalent to ≤ 10 mg/day of prednisone efficacy.
    • AddedWith any active infection requiring systemic anti-infective treatment at the time of first dose of study treatment.
    • AddedMajor surgery within 28 days prior to the first dose of the study drug, defined as: surgeries requiring at least 3 weeks of recovery to be able to receive treatment in this study.
    • AddedRadical radiation therapy within 3 months prior to study medications. Note: Palliative radiotherapy to bone or palliative radiotherapy to superficial lesions is allowed according to local standards 14 days prior to the first dose. Radiotherapy covering more than 30% of the bone marrow area within 28 days prior to the first dose is not allowed.
    • AddedThe subject has previously received other antibodies/drugs against immune checkpoints, such as PD-1, PD-L1, CTLA4, etc.
    • AddedParticipation in any other ongoing clinical studies, or less than 14 days from the end of the previous clinical study treatment to the start of this trial.
    • EditedPregnant or breastfeedinglactating females.
    • RemovedPatients with a known history of psychotropic drug abuse or drug addiction.
    • RemovedPatients who have other factors that could lead to the early termination of this study based on the investigator's judgment.
    • AddedActive use of psychotropics abuse or drug abuse.
    • AddedIn the judgment of the investigator, the subject has any other factors that may lead to a premature discontinuation.
    Secondary outcomes 11 added, 6 removed
    What changed in the outcomes
    • AddedObjective response rate (ORR)Time frame: approximately up to 14 months
    • AddedProgression-free survival (PFS)Time frame: approximately up to 24 months
    • AddedPFS2Time frame: Approximately up to 24 months
    • AddedDuration of response (DOR)Time frame: Approximately up to 24 months
    • AddedAdverse eventsTime frame: approximately up to 24 months
    • AddedObserved concentration of HLX10 in serumTime frame: Approximately up to 24 months
    • AddedEstimated PK exposure of HLX10 in serum from population pharmacokinetic analysis, expressed as mg·h/LTime frame: Approximately up to 24 months
    • AddedHLX10 anti-drug antibody (ADA)Time frame: Approximately up to 24 months
    • AddedNeutralizing antibody (NAb)Time frame: Approximately up to 24 months
    • AddedQuality of life assessmentTime frame: Approximately up to 24 months
    • RemovedORRTime frame: approximately up to 14 months
    • RemovedPFSTime frame: approximately up to 24 months
    • RemovedNumber of participants with treatment-related adverse events as assessed by CTCAE v5.0Time frame: approximately up to 24 months
    • RemovedMaximum Plasma Concentration (Cmax)Time frame: approximately up to 24 months
    • RemovedMinimum Plasma Concentration (Cmin)Time frame: approximately up to 24 months
    • RemovedAverage Plasma Concentration (Cavg)Time frame: approximately up to 24 months
    • Addedother outcomeExploratory EndpointTime frame: Approximately up to 24 months
    Design Phase 3→Phase 2
    + 2 other changes: verification date and date precision

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05468489
Responsible party
Sponsor
First posted
Jul 21, 2022
Start date
Nov 18, 2022
Primary completion
Feb 28, 2026
Completion
Dec 31, 2027 (estimated)
Last update
Nov 12, 2026

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion